Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wassim Abida

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Elife|September 5, 2018
Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and deathHaley Hieronymus, Rajmohan Murali, Amy Tin, et al.
Journal of Immunotherapy and Precision Oncology|December 25, 2023
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate CancerDaniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, et al.
European Urology Oncology|June 18, 2019
Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled TrialsSungmin Woo, Chong Hyun Suh, James A Eastham, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 3, 2025
BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex functionKyrie Pappas, Matteo Ferrari, Perianne Smith, et al.
European Urology Oncology|May 31, 2022
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the LiteratureAdam B Weiner, Aisha L Siebert, Sarah E Fenton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2026
Apalutamide + Abiraterone acetate plus Prednisone (AAP) + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase 2 StudySean M McBride, Daniel E Spratt, Marisa Kollmeier, et al.
European Urology|April 23, 2020
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical CharacteristicsBastien Nguyen, Jose Mauricio Mota, Subhiksha Nandakumar, et al.
Elife|September 12, 2017
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancerNeel Shah, Ping Wang, John Wongvipat, et al.
European Urology|April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) BluesNick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Elife|September 5, 2018
Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and deathHaley Hieronymus, Rajmohan Murali, Amy Tin, et al.
Journal of Immunotherapy and Precision Oncology|December 25, 2023
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate CancerDaniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, et al.
European Urology Oncology|June 18, 2019
Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled TrialsSungmin Woo, Chong Hyun Suh, James A Eastham, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 3, 2025
BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex functionKyrie Pappas, Matteo Ferrari, Perianne Smith, et al.
European Urology Oncology|May 31, 2022
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the LiteratureAdam B Weiner, Aisha L Siebert, Sarah E Fenton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2026
Apalutamide + Abiraterone acetate plus Prednisone (AAP) + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase 2 StudySean M McBride, Daniel E Spratt, Marisa Kollmeier, et al.
European Urology|April 23, 2020
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical CharacteristicsBastien Nguyen, Jose Mauricio Mota, Subhiksha Nandakumar, et al.
Elife|September 12, 2017
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancerNeel Shah, Ping Wang, John Wongvipat, et al.
European Urology|April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) BluesNick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Pageof 9